The detection of ROS1 rearrangement in stage IIIB/IV non-small cell lung cancer (NSCLC) patients makes them eligible for targeted therapy, notably for administration of the tyrosine-kinase inhibitor crizotinib [1,2]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.